Hannes Kubo1, Sarah Czerwinski1, Holger Schrumpf1, Bettina Buhren1, Peter Prodinger2, Ruediger Krauspe3, Hakan Pilge4. 1. University of Duesseldorf, Medical Faculty, Department of Orthopaedics and Trauma Surgery, Clinic Director: Prof. Joachim Windolf, Moorenstr. 5, D-40225, Duesseldorf, Germany. 2. Krankenhaus Agatharied, Abteilung für Unfallchirurgie und Orthopädie, Norbert Kerkel Platz, D-83734, Hausham, Germany. 3. Professor Emeritus of the Orthopedic Department, University Duesseldorf, Germany. 4. Orthopaedicum Munich, Charles-de-Gaulle-Str. 4, 81737, Munich, Germany.
Abstract
BACKGROUND: The effects of rifampicin and clindamycin on human mesenchymal stromal cell (hMSC) were examined. METHODS: hMSC were cultured with rifampicin and clindamycin (0.5 μg/ml, 5 μg/ml, 50 μg/ml) and examinations of proliferation (Bromodeoxyuridine), calcification (Alizarin red) and mineralization (alkaline phosphatase) were performed after 7th, 14th and 21st days. RESULTS: With rifampicin (50 μg/ml) cultured hMSC showed a significant negative effect during proliferation, mineralization (7, 14 and 21 days) and calcification (21 days). Clindamycin seems to have no effect. CONCLUSIONS: Rifampicin in a dosage of 50 μg/ml showed a negative impact on proliferation, mineralization and calcification of hMSC after 21 days.
BACKGROUND: The effects of rifampicin and clindamycin on human mesenchymal stromal cell (hMSC) were examined. METHODS: hMSC were cultured with rifampicin and clindamycin (0.5 μg/ml, 5 μg/ml, 50 μg/ml) and examinations of proliferation (Bromodeoxyuridine), calcification (Alizarin red) and mineralization (alkaline phosphatase) were performed after 7th, 14th and 21st days. RESULTS: With rifampicin (50 μg/ml) cultured hMSC showed a significant negative effect during proliferation, mineralization (7, 14 and 21 days) and calcification (21 days). Clindamycin seems to have no effect. CONCLUSIONS: Rifampicin in a dosage of 50 μg/ml showed a negative impact on proliferation, mineralization and calcification of hMSC after 21 days.
Authors: Christopher R Rathbone; Jessica D Cross; Kate V Brown; Clinton K Murray; Joseph C Wenke Journal: J Orthop Res Date: 2011-02-24 Impact factor: 3.494
Authors: Y El Samad; E Havet; H Bentayeb; B Olory; B Canarelli; J-F Lardanchet; Y Douadi; F Rousseau; F-X Lescure; P Mertl; F Eb; J-L Schmit Journal: Med Mal Infect Date: 2008-08-20 Impact factor: 2.152
Authors: T N Peel; K L Buising; M M Dowsey; C A Aboltins; J R Daffy; P A Stanley; P F M Choong Journal: Antimicrob Agents Chemother Date: 2012-10-31 Impact factor: 5.191
Authors: H Pilge; J Fröbel; P M Prodinger; S J Mrotzek; J C Fischer; C Zilkens; B Bittersohl; R Krauspe Journal: Bone Joint Res Date: 2016-03 Impact factor: 5.853
Authors: Hakan Pilge; Julia Fröbel; Silvia J Mrotzek; Johannes C Fischer; Peter M Prodinger; Christoph Zilkens; Bernd Bittersohl; Rüdiger Krauspe Journal: BMC Musculoskelet Disord Date: 2016-03-01 Impact factor: 2.362
Authors: Hakan Pilge; Julia Fröbel; Sabine Lensing-Höhn; Christoph Zilkens; Rüdiger Krauspe Journal: Biomed Res Int Date: 2016-03-16 Impact factor: 3.411